Should you buy Myriad Genetics stock? (NasdaqGS:MYGN). Let's see how it does in our automated value investing analysis system.
Based on historical returns, we believe that Myriad Genetics can grow its free cash at a rate of about 5%. That's positive!
(Myriad Genetics stock price per share)
|MYGN Fair Price
(based on intrinsic value)
|MYGN Safety Price (based on a variable margin of safety)||$16.24|
|PE Ratio versus Sector||1984% higher than other Healthcare stocks|
|PE Ratio versus Industry||49% lower than other Diagnostics & Research stocks|
|Free Cash Flow Jitter||26%|
We believe that Myriad Genetics may be worth examining further. It's making money, which is a very positive sign. Is it on sale?
Myriad Genetics looks like a price in the fair value range. Based on our analysis—if the company keeps making money the way it has been—you could be looking at a good stock. See Before You Buy for your next steps.
Does Myriad Genetics have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.
Most Popular Articles